Cargando…

Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awareness

Amyloid transthyretin (ATTR) amyloidosis is a clinically heterogeneous and fatal disease that results from deposition of insoluble amyloid fibrils in various organs and tissues, causing progressive loss of function. The objective of this review is to increase awareness and diagnosis of ATTR amyloido...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nativi-Nicolau, Jose N., Karam, Chafic, Khella, Sami, Maurer, Mathew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9033715/ https://www.ncbi.nlm.nih.gov/pubmed/33609196 http://dx.doi.org/10.1007/s10741-021-10080-2

Ejemplares similares

Impact of Delayed Diagnosis and Misdiagnosis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): A Targeted Literature Review
por: Rozenbaum, Mark H., et al.
Publicado: (2021)

ATTR amyloidosis during the COVID-19 pandemic: insights from a global medical roundtable
por: Brannagan, Thomas H., et al.
Publicado: (2021)

The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023)

Quality of life in ATTR amyloidosis
por: Lane, Thirusha, et al.
Publicado: (2015)

Guidelines for genetic counselling in ATTR amyloidosis
por: Sequeiros, Jorge
Publicado: (2015)

Heart transplantation in hereditary ATTR amyloidosis
por: Slama, M
Publicado: (2015)

Diagnosis and Treatment of AL and ATTR Amyloidosis
por: Faiman, Beth, et al.
Publicado: (2021)

Avoiding misdiagnosis: expert consensus recommendations for the suspicion and diagnosis of transthyretin amyloidosis for the general practitioner
por: Gertz, Morie, et al.
Publicado: (2020)

Natural history and progression of transthyretin amyloid cardiomyopathy: insights from ATTR‐ACT
por: Nativi‐Nicolau, Jose, et al.
Publicado: (2021)

ATTR Amyloidosis: Current and Emerging Management Strategies: JACC: CardioOncology State-of-the-Art Review
por: Griffin, Jan M., et al.
Publicado: (2021)

ATTR Amyloidosis: development of cardiac symptoms during 6 years of follow up in different ATTR-variants
por: Klaassen, Sebastiaan, et al.
Publicado: (2015)

Glavonoid, a possible supplement for prevention of ATTR amyloidosis
por: Matsushita, Hiroaki, et al.
Publicado: (2021)

Quality of life assessment in amyloid transthyretin (ATTR) amyloidosis
por: Aimo, Alberto, et al.
Publicado: (2021)

Conventional heart failure therapy in cardiac ATTR amyloidosis
por: Ioannou, Adam, et al.
Publicado: (2023)

Cardiac amyloidosis: diagnostic challenges and recent advancement in the treatment of transthyretin amyloidosis (ATTR)
por: Rahman, Tanvir, et al.
Publicado: (2021)

A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis)
por: Gonzalez-Duarte, Alejandra, et al.
Publicado: (2021)

Hepatic Amyloidosis With Multiorgan Involvement
por: Duve, Robert J., et al.
Publicado: (2023)

A Descriptive Analysis of ATTR Amyloidosis in Spain from the Transthyretin Amyloidosis Outcomes Survey
por: González-Moreno, Juan, et al.
Publicado: (2021)

Diagnosis and Screening of Patients with Hereditary Transthyretin Amyloidosis (hATTR): Current Strategies and Guidelines
por: Benson, M D, et al.
Publicado: (2020)

The landscape of treatment of chronic kidney disease in hereditary ATTR amyloidosis
por: Lobato, Luisa
Publicado: (2015)

TUDCA as an autophagic modulator of ATTR V30M Amyloidosis
por: Teixeira, Cristina, et al.
Publicado: (2015)

The role of complement in ATTR amyloidosis: a new therapeutic avenue?
por: Panayiotou, Elena, et al.
Publicado: (2015)

Symptomatic therapy in ATTR amyloidosis: pain killers in TTR-FAP
por: Attal, Nadine
Publicado: (2015)

Hereditary ATTR Amyloidosis in Austria: Prevalence and Epidemiological Hot Spots
por: Auer-Grumbach, Michaela, et al.
Publicado: (2020)

Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy
por: Adams, David, et al.
Publicado: (2020)

Practice of Hereditary ATTR Amyloidosis in Non-endemic Areas of Japan
por: Matsushima, Masaaki, et al.
Publicado: (2022)

Early Data on Long-term Impact of Inotersen on Quality-of-Life in Patients with Hereditary Transthyretin Amyloidosis Polyneuropathy: Open-Label Extension of NEURO-TTR
por: Yarlas, Aaron, et al.
Publicado: (2021)

Apolipoprotein C-II Deposition Amyloidosis: A Potential Misdiagnosis as Light Chain Amyloidosis
por: Lohani, Sadichhya, et al.
Publicado: (2016)

Patient and family experience with transthyretin amyloid cardiomyopathy (ATTR-CM) and polyneuropathy (ATTR-PN) amyloidosis: results of two focus groups
por: Rintell, David, et al.
Publicado: (2021)

Do we need to demonstrate amyloid in tissue for hereditary ATTR amyloidosis ?
por: Westermark, Per
Publicado: (2015)

Unusual case of ATTR amyloidosis with cardiac manifestation and situs inversus totalis
por: Fritschka, Max, et al.
Publicado: (2017)

Genetic background modifies amyloidosis in a mouse model of ATTR neuropathy
por: Panayiotou, E., et al.
Publicado: (2016)

Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: a review
por: Cruz, Márcia Waddington
Publicado: (2019)

World Heart Federation Consensus on Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
por: Brito, Dulce, et al.
Publicado: (2023)

Phase 3 Multicenter Study of Revusiran in Patients with Hereditary Transthyretin-Mediated (hATTR) Amyloidosis with Cardiomyopathy (ENDEAVOUR)
por: Judge, Daniel P., et al.
Publicado: (2020)

Unique skin manifestations of hereditary apolipoprotein A-1 amyloidosis
por: Moshe-Lilie, Orly, et al.
Publicado: (2020)

Multiorgan involvement by amyloid light chain amyloidosis
por: Li, Guoliang, et al.
Publicado: (2019)

Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report
por: Dattilo, Philip B
Publicado: (2009)

Patients with hereditary ATTR amyloidosis experience an increasing burden of illness as the disease progresses
por: Adams, David, et al.
Publicado: (2015)

Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy
por: Gentile, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0vi3q11sus6473ko8515ai1r6b